A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China
Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative t...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-09-01
|
Series: | Integrative Cancer Therapies |
Online Access: | https://doi.org/10.1177/1534735418775819 |
id |
doaj-4f94c5299b924f2d8e98552288680ff3 |
---|---|
record_format |
Article |
spelling |
doaj-4f94c5299b924f2d8e98552288680ff32020-11-25T03:20:48ZengSAGE PublishingIntegrative Cancer Therapies1552-695X2018-09-011710.1177/1534735418775819A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in ChinaLingling Sun0Paul Fahey1Xiaoshu Zhu2Weng Ng3Zhuo Ping Chen4Yiwen Qiu5Hezheng Lai6Jietao Lin7Lizhu Lin8Guangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, ChinaWestern Sydney University, Campbelltown, New South Wales, AustraliaWestern Sydney University, Campbelltown, New South Wales, AustraliaSouth West Sydney Local Health District, Liverpool, New South Wales, AustraliaGuangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, ChinaGuangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, ChinaWestern Sydney University, Campbelltown, New South Wales, AustraliaGuangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, ChinaGuangzhou University of Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, ChinaBackground. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups ( P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement.https://doi.org/10.1177/1534735418775819 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lingling Sun Paul Fahey Xiaoshu Zhu Weng Ng Zhuo Ping Chen Yiwen Qiu Hezheng Lai Jietao Lin Lizhu Lin |
spellingShingle |
Lingling Sun Paul Fahey Xiaoshu Zhu Weng Ng Zhuo Ping Chen Yiwen Qiu Hezheng Lai Jietao Lin Lizhu Lin A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China Integrative Cancer Therapies |
author_facet |
Lingling Sun Paul Fahey Xiaoshu Zhu Weng Ng Zhuo Ping Chen Yiwen Qiu Hezheng Lai Jietao Lin Lizhu Lin |
author_sort |
Lingling Sun |
title |
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title_short |
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title_full |
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title_fullStr |
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title_full_unstemmed |
A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China |
title_sort |
cohort study to examine the use of chinese herbal medicine in combination with conventional therapies for patients with hepatocellular carcinoma in china |
publisher |
SAGE Publishing |
series |
Integrative Cancer Therapies |
issn |
1552-695X |
publishDate |
2018-09-01 |
description |
Background. Hepatocellular carcinoma (HCC) is one of the major malignancies associated with high mortality rates. Chinese herbal medicine (CHM) alone, or in combination with conventional therapies (CT), has been widely used for patients with HCC in China. This study aims to explore how integrative therapy (IT) through the combination of CHM and CT affects the survival of patients with intermediate-advanced HCC. Methods. A retrospective cohort study was performed at the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Data of consecutive patients diagnosed with intermediate-advanced HCC and a specific traditional Chinese medicine diagnostic pattern between January 2006 and December 2013 were retrieved from the electronic medical record system at the hospital. Patients were divided into 3 groups based on the therapies used, that is, IT, CHM alone, and CT alone, and the survival times of these patients was compared. Results. A total of 328 patients were included in this study. Median follow-up period was 26.4 months (95% confidence interval [CI] = 22.7-38.9). Median overall survival was 11.0 months for IT, 8.6 months for CHM, and 9.4 months for CT groups ( P < .001). The adjusted hazard ratio (HR) of death for the IT group was 0.55 (95% CI = 0.38-0.79, P = .001) relative to the CT group and 0.68 (95% CI = 0.52-0.90, P = .007) relative to the CHM group, after adjusting for the factors that impact prognosis. Stratified analysis shows that IT can significantly lower the risk of death, especially for patients with good performance status (PS) and Child-Pugh class A. Conclusions. It was indicated that the integrative approach with combination of CHM and CT might improve survival for patients with intermediate-advanced HCC, especially for patients with good PS and Child-Pugh class A. However, a randomized controlled trial is warranted for a conclusive statement. |
url |
https://doi.org/10.1177/1534735418775819 |
work_keys_str_mv |
AT linglingsun acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT paulfahey acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT xiaoshuzhu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT wengng acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT zhuopingchen acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT yiwenqiu acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT hezhenglai acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT jietaolin acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT lizhulin acohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT linglingsun cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT paulfahey cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT xiaoshuzhu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT wengng cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT zhuopingchen cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT yiwenqiu cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT hezhenglai cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT jietaolin cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina AT lizhulin cohortstudytoexaminetheuseofchineseherbalmedicineincombinationwithconventionaltherapiesforpatientswithhepatocellularcarcinomainchina |
_version_ |
1715240800635322368 |